(AVBP) ArriVent BioPharma - Performance 19.9% in 12m
AVBP performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
9.87%
#28 in Peer-Group
Rel. Strength
66.95%
#2451 in Stock-Universe
Total Return 12m
19.94%
#49 in Peer-Group
Total Return 5y
20.94%
#30 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 35.63 USD |
| 52 Week Low | 16.30 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 28.51 |
| Buy/Sell Signal +-5 | -1.88 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: AVBP (19.9%) vs XBI (-10.8%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
2.52% | 66.7% | 77.4% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-11.7% | -9.92% | 139% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
-3.21% | -7.33% | 26.4% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
-0.28% | 31.9% | -4.56% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
0.91% | -10.3% | 0.26% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.3% | 65.1% | -9.72% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
0.02% | 56.7% | -7.85% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
2.86% | 34.5% | 14.3% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: AVBP vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for AVBP
| Total Return (including Dividends) | AVBP | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -1.05% | 2.09% | 4.55% |
| 3 Months | 17.74% | 2.27% | 10.78% |
| 12 Months | 19.94% | -10.84% | 14.71% |
| 5 Years | 20.94% | -26.24% | 112.53% |
| Trend Score (consistency of price movement) | AVBP | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 2.2% | 18.8% | 79.2% |
| 3 Months | 84% | 71.5% | 92.9% |
| 12 Months | -22.9% | -84.3% | 44.2% |
| 5 Years | 35.9% | -52.7% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th53.00 | -3.07% | -5.35% |
| 3 Month | %th67.00 | 15.13% | 6.28% |
| 12 Month | %th76.00 | 34.52% | 4.56% |
| 5 Years | %th82.00 | 28.87% | -6.24% |
FAQs
Does ArriVent BioPharma (AVBP) outperform the market?
Yes,
over the last 12 months AVBP made 19.94%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.84%.
Over the last 3 months AVBP made 17.74%, while XBI made 2.27%.
Performance Comparison AVBP vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
AVBP vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -7.5% | -5.6% | -24.3% | 5% |
| US NASDAQ 100 | QQQ | -8.3% | -6.6% | -26.5% | 5% |
| German DAX 40 | DAX | -7.3% | -1.1% | -37.3% | -10% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -7.1% | -5.2% | -22.3% | 2% |
| Hongkong Hang Seng | HSI | -7.1% | -6.8% | -40.1% | -16% |
| India NIFTY 50 | INDA | -7% | -3.1% | -24.1% | 20% |
| Brasil Bovespa | EWZ | -8.8% | -8.8% | -48.8% | 7% |
AVBP vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -9% | -7.8% | -31% | -9% |
| Consumer Discretionary | XLY | -5.9% | -2.7% | -15.6% | 0% |
| Consumer Staples | XLP | -4% | 0.6% | -22.5% | 11% |
| Energy | XLE | -3.1% | -4.6% | -18.9% | 24% |
| Financial | XLF | -7.6% | -4.1% | -27.4% | -9% |
| Health Care | XLV | -6.5% | -3.1% | -17.1% | 25% |
| Industrial | XLI | -7.1% | -4.8% | -30.9% | -4% |
| Materials | XLB | -5.5% | -2.7% | -23.7% | 17% |
| Real Estate | XLRE | -3% | -1.1% | -21.7% | 7% |
| Technology | XLK | -8.8% | -9.9% | -27.6% | 8% |
| Utilities | XLU | -5% | -1.1% | -27.7% | -4% |
| Aerospace & Defense | XAR | -9.4% | -10.9% | -45.7% | -33% |
| Biotech | XBI | -5.3% | -3.1% | -10.4% | 31% |
| Homebuilder | XHB | -5.7% | -7.1% | -13.1% | 19% |
| Retail | XRT | -4.4% | -2.5% | -15.6% | 14% |
AVBP vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -0.2% | -6.17% | -15.1% | 30% |
| Natural Gas | UNG | 4.7% | 8.4% | -9.2% | 28% |
| Gold | GLD | -2.5% | 1.1% | -44.2% | -21% |
| Silver | SLV | -4.1% | -4.9% | -42.9% | -2% |
| Copper | CPER | -7.8% | -5.2% | -44% | 5% |
AVBP vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -6.2% | -4.7% | -21.1% | 18% |
| iShares High Yield Corp. Bond | HYG | -5.4% | -2.9% | -23.3% | 9% |